Friday, May 26, 2006

Raloxifene (Evista) may increase risk of stroke

In April, U.S. researchers reported raloxifene works as well as tamoxifen at cutting the risk of invasive breast cancer in half among post-menopausal women who take it every day. Unlike tamoxifen, raloxifene was less likely to lead to uterine cancer or potentially dangerous blood clots. But now the drug's manufacturer, Eli Lilly, says it has uncovered stroke risks. The finding was made during a study designed to see if raloxifene reduced the risk of heart disease and breast cancer in postmenopausal women who had heart disease or were considered at high risk. The study of 10,000 women found the incidence of stroke mortality was 1.5 per 1,000 women per year taking a placebo, compared to 2.2 per 1,000 per year for raloxifene, the company said. --Click the title of this post to read the full article from its source--


Post a Comment

<< Home

/* WebRing Code */